TNXP NASDAQ
Tonix Pharmaceuticals Holding Corp.
1W: -0.6%
1M: +6.8%
3M: -0.3%
YTD: -15.4%
1Y: -53.2%
3Y: -99.8%
5Y: -100.0%
$12.77
-1.23 (-8.79%)
Weekly Expected Move ±11.3%
$12
$14
$16
$18
$19
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (42)
TNXP: Secures Commercial Payer Coverage for Tonmya® to Provide Access for ~35 Million U.S. Patients
[10-Q] Tonix Pharmaceuticals Holding Corp. Quarterly Earnings Report - Stock Titan
Tonix Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational Highlights
Why Tonix Pharmaceuticals Shares Are Rallying Wednesday
Tonix rises on commercial payer coverage for pain therapy
Tonix Pharmaceuticals Announces Presentation of Phase 1 Data and Plans for an Adaptive Phase 2 Field Study of TNX-4800 (anti-Borrelia OspA monoclonal antibody) for the Prevention of Lyme Disease at the 4th Annual Ticks and Tickborne Diseases Symposium at Johns Hopkins University
Tonix Pharmaceuticals Presents Updates on Preclinical Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2026
Tonix Pharmaceuticals Presents Updates on Preclinical Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2026
Tonix Pharmaceuticals Announces Presentation of Phase 1 Data and Outlines Planned Adaptive Phase 2 Field Study of TNX-4800 for the Prevention of Lyme Disease, at the World Vaccine Congress Washington 2026
Tonix Pharmaceuticals Announces Presentation of Phase 1 Data and Outlines Planned Adaptive Phase 2 Field Study of TNX-4800 for the Prevention of Lyme Disease, at the World Vaccine Congress Washington 2026
Tonix Pharmaceuticals Stock Hits New 52-Week Low: What's Driving The Action?
Catalyst Watch: Jobs report, Nike earnings, and Apple turns 50
What is Zacks Research’s Forecast for TNXP Q1 Earnings?
Tonix Pharmaceuticals Announces First Participant Dosed in Phase 1 Investigator-Initiated Pharmacodynamic Study of TNX-1900 (Intranasal Potentiated Oxytocin) to Assess Potential for Treating Migraine and Craniofacial Pain
FY2028 Earnings Estimate for TNXP Issued By Zacks Research
Tonix Pharmaceuticals Announces Presentations at World Vaccine Congress Washington 2026
Tonix Pharmaceuticals Announces Presentations at World Vaccine Congress Washington 2026
TNXP: ~2500 Patients Have Initiated Treatment with Tonmya Following November 2025 Commercial Launch
12 Health Care Stocks Moving In Thursday's Intraday Session
What is Noble Financial’s Forecast for TNXP Q1 Earnings?
Tonix Pharmaceuticals to Present at BIO-Europe Spring 2026
Tonix Pharmaceuticals Announces Oral Presentation and Two Poster Presentations on Preclinical Immuno-oncology Portfolio at the American Association for Cancer Research (AACR) Annual Meeting 2026
Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing
Tonix Pharmaceuticals Says Prescriptions For Chronic Pain Drug Top 4,200 Since Launch
Tonix Pharmaceuticals GAAP EPS of -$3.98 misses by $0.82, revenue of $5.39M beats by $2.42M
Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
Life Sciences Virtual Investor Forum Agenda Announced for March 11th & 12th
Tonix Pharmaceuticals Presented Data on TONMYATM in Treating Patients with Fibromyalgia at the 2026 AAPM PainConnect Annual Meeting
Tonix Pharmaceuticals Announces Publication of Clinical Pharmacokinetic Studies of TONMYA™ and Prototype Formulations in the Journal Clinical Pharmacology in Drug Development
Tonix Pharmaceuticals to Present Poster on Tonmya™ at the 2026 American Academy of Pain Medicine PainConnect Annual Meeting
Tonix Pharmaceuticals Stock Dips After Nasdaq Uplisting
Tonix Pharmaceuticals to Participate in Two Investor Conferences in March
Tonix Pharmaceuticals Presented Phase 3 RESILIENT Data on TONMYA™ (Cyclobenzaprine HCl Sublingual Tablets) at the 2026 Non-Opioid Pain Therapeutics Summit
Tonix Pharmaceuticals to Present at Two Investor Conferences in January 2026
Tonix Pharmaceuticals Announces Pricing of $20.0 Million Registered Direct Offering
Tonix Pharmaceuticals Announces Program Updates on Phase 2/3-Ready Long-Acting Monoclonal Antibody (mAb) Designed for Seasonal Prevention of Lyme Disease (TNX-4800)
Tonix Pharmaceuticals (NASDAQ:TNXP) & Citius Pharmaceuticals (NASDAQ:CTXR) Head to Head Contrast
Tonix Pharmaceuticals Announces Licensing TNX-4900, a Selective Sigma-1 Receptor Antagonist for Chronic Neuropathic Pain from Rutgers University
Tonix Pharmaceuticals Appoints Irina Ishak as General Counsel
Tonix: Maintaining Buy Rating With Potential Tonmya Expansion Indications
Tonix Pharmaceuticals Announces FDA IND Clearance for Phase 2 Study of TNX-102 SL for the Treatment of Major Depressive Disorder